For heavily treatment-experienced adults with HIV-1 failing therapy. See Full Indication.

Edge of Yesterday Podcast

edge of yesterday sub hero image
edge of yesterday sub hero image

Edge of Yesterday, a podcast series, takes you on a journey from the early days of the AIDS epidemic up to the present day. Reflecting on the many milestones along the way reminds us of a subset of patients still in need. Each episode covers an important topic with firsthand accounts. 

A WINDOW TO THE PAST

Episode 1: A WINDOW TO THE PAST

Guests: Golkoo Morcos, Dr. Michael Gottlieb, and Marty St. Clair

20
20
headshots desktop
headshots mobile

EPISODE 1

Golkoo Morcos, US medical director at ViiV Healthcare, talks to two early pioneers in AIDS treatment and research, Dr. Michael Gottlieb and Marty St. Clair. Hear what it was like to be involved in the development and impact of early HIV-1 treatment. They will also discuss their points of view on RUKOBIA, an option for heavily treatment-experienced patients living with HIV-1.

Featured Guests

Dr. Gottlieb was responsible for describing the syndrome of opportunistic infections in CD4+ T-cell deficiency that characterized the condition that later became to be known as AIDS. Dr. Gottlieb also authored the first report of the syndrome to the Centers for Disease Control and Prevention, which was published on June 5, 1981, in Morbidity and Mortality Weekly Report, and would later write about a set of AIDS cases that were published in the New England Journal of Medicine.

Marty St. Clair, a virologist at ViiV Healthcare, has been working as a research scientist since the early 1980s. She was a part of the team that discovered and helped develop the first HIV drug, azidothymidine, otherwise known as AZT, or zidovudine. 

To view references for “A Window to the Past,” click here.

 

References:

  1. ViiV Healthcare. Treating HIV: Building On 30 Years of Innovation, Ingenuity and Passion. https://viivhealthcare.com/en-gb/our-stories/our-people/treating-hiv-building-on-30-years-of-innovation-ingenuity-and-passion/
  2. Gottlieb MS. AIDS—past and future. N Engl J Med. 2001;344(23):1788-1791. doi: 10.1056/NEJM200106073442312
  3. Centers for Disease Control and Prevention (CDC). AIDS: the Early Years and CDC’s Response. MMWR. 2011;60(04):64-69.
  4. Fee E, Brown TM. Michael S. Gottlieb and the identification of AIDS. Am J Public Health. 2006;96(6):982-983. doi: 10.2105/AJPH.2006.088435
  5. National Institute of Allergy and Infectious Diseases (NIAID). Antiretroviral Drug Discovery and Development. Accessed June 1, 2021. https://www.niaid.nih.gov/diseases-conditions/antiretroviral-drug-development
  6. National Institutes of Health (NIH). In Their Own Words; NIH Researchers Recall the Early Years of AIDS. Discovery of HIV. Department of Health and Human Services. Accessed June 1, 2021. https://history.nih.gov/display/history/Discovery+of+HIV
  7. Shampo MA, Kyle RA. Luc Montagnier—discoverer of the AIDS virus. Mayo Clin Proc. 2002;77(6):506. doi: 10.4065/77.6.506
  8. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Department of Health and Human Services. Updated May 26, 2020. Accessed June 1, 2020. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf
  9. Deeks SG, Overbaugh J, Phillips A, Buchbinder S. HIV infection. Nat Rev Dis Primers. 2015;1(15035):1-22.  doi: 10.1038/nrdp.2015.35
  10. National Institutes of Health (NIH). In Their Own Words; NIH Researchers Recall the Early Years of AIDS. First Encounters. Department of Health and Human Services. Accessed June 1, 2021. https://history.nih.gov/display/history/First+Encounters
  11. Centers for Disease Control and Prevention (CDC). Pneumocystis Pneumonia—Los Angeles. MMWR. 1981;30(21):1-3.
  12. Quinn TC. HIV epidemiology and the effects of antiviral therapy on long-term consequences. AIDS. 2008;Suppl 3(Suppl 3):S7-S12. doi: 10.1097/01.aids.0000327510.68503.e8
  13. Cochrane J. Zidovudine’s patent history. The Lancet. 2000;356(9241):1611-1612. Accessed June 1, 2021. https://www.thelancet.com/action/showPdf?pii=S0140-6736%2805%2974463-9
  14. McHugh J. A tap and drain: sinking CD4+ T cells. Nature Milestones. Accessed June 16, 2021. https://media.nature.com/original/magazine-assets/d42859-018-00014-8/d42859-018-00014-8.pdf
  15. Lataillade M, Lalezari JP, Kozal M, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. Lancet HIV. 2020;7(11):e740-e751. doi: 10.1016/S2352-3018(20)30240-X
  16. Data on file, ViiV Healthcare.
  17. Cutrell J, Jodlowski T, Bedimo R. The management of treatment-experienced HIV patients (including virologic failure and switches). Ther Adv Infectious Dis. 2020(7):1-15. doi: 10.1177/2049936120901395
  18. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Updated June 3, 2021. Accessed June 1, 2021. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf

FSTWCNT210014